Transcatheter closure of congenital ventricular septal defects: results of the European Registry

Abstract

Transcatheter closure of congenital VSDs offers encouraging results. COMPLICATIONS are limited; the most relevant one seems to be the device related to cAVB in perimembranous VSD. More experience and long-term follow-up are mandatory to assess safety and effectiveness of this procedure as an alternative to conventional surgery.

Echocardiographic Evaluation of Cardiac Remodeling After Surgical Closure of Ventricular Septal Defect in Different Age Group

“…According to their location within the septum, defects can be classified as muscular, perimembranous and supracristal 10 . The most common are the perimembranous VSD which is consistent with the present study result 4 . This perimembranous VSD (PMVSD) is the most common hemodynamically significant VSD 1 .…”

“…Prevalence rate of ventricular septal defects (VSDs) is varied from 0.44 and 0.48 per 1000 in four successive years of study in elementary school children 3 . The traditional treatment of VSD is surgical repair 4 . Since 1954, when the first surgical closure of a PMVSD took place, there have been considerable changes in the surgical strategy for closure in terms of timing, perfusion modalities and approach, making surgical closure a relatively low risk procedure 1 .…”

Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac Disease

“…[55][56][57][58] Children Ն5 kg in weight and with favorable anatomy are considered candidates for percutaneous closure. For infants who weigh Ͻ5 kg or for patients with abnormal septal wall planes, percutaneous MVSD device closure carries additional risk beyond the procedure-and device-related adverse events.…”

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

“…Patients undergoing device closure systematically receive 100 U/kg UFH intravenously at implantation and are discharged on an antiplatelet agent such as low-dose aspirin for 6 months. [666][667][668] Among the multiple series published on transcatheter closure of ventricular septal defects, device-related thrombosis has not been reported as a procedural complication. [666][667][668][669][670][671] Thus, it appears that the common practice of using aspirin therapy for 6 months is effective thromboprophylaxis, although there are no studies addressing the safety and efficacy of aspirin.…”